BR0309491A - Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes - Google Patents
Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantesInfo
- Publication number
- BR0309491A BR0309491A BR0309491-0A BR0309491A BR0309491A BR 0309491 A BR0309491 A BR 0309491A BR 0309491 A BR0309491 A BR 0309491A BR 0309491 A BR0309491 A BR 0309491A
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- acid sequence
- protein
- composition
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"COMPOSIçãO DE VACINA, COMPOSIçãO IMUNOGêNICA, UTILIZAçãO DE UMA PROTEìNA E7 E ANTICORPOS NEUTRALIZANTES". A invenção trata de uma composição imunogênica ou de vacina que induz uma resposta imunitária ao encontro da proteína E7 nativa do Papillomavirus HPV-16, sem induzir simultaneamente uma imunossupressão, a dita composição compreendendo, a título de princípio ativo, uma proteína E7 mutada não imunossupressora compreendendo a sequência de aminoácidos consiste da extremidade N-terminal para a extremidade C-terminal: (i) na sequência de aminoácidos 1-19 da sequência SEQ ID N<0> 3; (ii) em uma sequência de aminoácidos possuindo (a) a substituição de pelo menos um aminoácido, em relação à sequência correspondente de aminoácidos consecutivos em relação à sequência correspondente de aminoácidos 20-29 da sequência SEQ ID N<0> 3 ou (b) a deleção de pelo menos quatro aminoácidos consecutivos em relação à sequência correspondente de aminoácidos 20-29 da sequência SEQ ID N<0> 3; e (iii) na sequência de aminoácidos 30-98 da sequência SEQ ID N<0> 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0205173A FR2839072A1 (fr) | 2002-04-24 | 2002-04-24 | Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation |
| PCT/FR2003/001082 WO2003090667A2 (fr) | 2002-04-24 | 2003-04-04 | Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309491A true BR0309491A (pt) | 2005-02-15 |
Family
ID=28799908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0309491-0A BR0309491A (pt) | 2002-04-24 | 2003-04-04 | Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7314629B2 (pt) |
| EP (1) | EP1509543B1 (pt) |
| JP (1) | JP2005532298A (pt) |
| CN (1) | CN1656116A (pt) |
| AT (1) | ATE408620T1 (pt) |
| AU (1) | AU2003249143B2 (pt) |
| BR (1) | BR0309491A (pt) |
| CA (1) | CA2483819C (pt) |
| DE (1) | DE60323634D1 (pt) |
| DK (1) | DK1509543T3 (pt) |
| ES (1) | ES2312801T3 (pt) |
| FR (1) | FR2839072A1 (pt) |
| WO (1) | WO2003090667A2 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417430D0 (en) * | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| US8399610B2 (en) * | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| US8452541B2 (en) * | 2007-06-18 | 2013-05-28 | Microsoft Corporation | Vaccine design methodology |
| US20090117140A1 (en) * | 2007-09-26 | 2009-05-07 | Mayumi Nakagawa | Human papilloma virus dominant CD4 T cell epitopes and uses thereof |
| US8466259B2 (en) * | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
| JP5146113B2 (ja) * | 2008-05-30 | 2013-02-20 | 住友電装株式会社 | 電気接続箱 |
| US8287880B2 (en) | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
| CN102482327B (zh) * | 2009-06-22 | 2014-10-29 | 财团法人卫生研究院 | 脂质化肿瘤相关抗原及其免疫治疗的组成物及方法 |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| CN105177048B (zh) * | 2014-08-12 | 2018-02-02 | 广东拓谱康生物科技有限公司 | 携带人乳头瘤病毒16型多点突变型E7mm抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN105177047B (zh) * | 2014-08-12 | 2018-02-02 | 广东拓谱康生物科技有限公司 | 携带人乳头瘤病毒16型突变型E7m94抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| CN114075293B (zh) * | 2020-08-14 | 2022-11-15 | 长沙诺盟生物医药有限公司 | 包含突变的hpv16 e6蛋白的融合蛋白和疫苗组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2038581A1 (en) * | 1990-03-20 | 1991-09-21 | Martin Muller | Seroreactive epitopes of human papillomavirus (hpv) 16 proteins |
| AUPN015794A0 (en) * | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
| GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| AU766403C (en) * | 1998-09-04 | 2004-05-27 | Aventis Pasteur Limited | Treatment of cervical cancer |
| CA2381991A1 (en) * | 1999-08-25 | 2001-03-01 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| FR2794371B1 (fr) * | 1999-10-07 | 2004-06-18 | Biovector Therapeutics | Fragments proteiquespolyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
-
2002
- 2002-04-24 FR FR0205173A patent/FR2839072A1/fr active Pending
-
2003
- 2003-04-04 AU AU2003249143A patent/AU2003249143B2/en not_active Ceased
- 2003-04-04 DK DK03747137T patent/DK1509543T3/da active
- 2003-04-04 WO PCT/FR2003/001082 patent/WO2003090667A2/fr active IP Right Grant
- 2003-04-04 US US10/512,045 patent/US7314629B2/en not_active Expired - Fee Related
- 2003-04-04 DE DE60323634T patent/DE60323634D1/de not_active Expired - Lifetime
- 2003-04-04 CN CNA03811786XA patent/CN1656116A/zh active Pending
- 2003-04-04 JP JP2003587306A patent/JP2005532298A/ja active Pending
- 2003-04-04 EP EP03747137A patent/EP1509543B1/fr not_active Expired - Lifetime
- 2003-04-04 CA CA2483819A patent/CA2483819C/fr not_active Expired - Fee Related
- 2003-04-04 AT AT03747137T patent/ATE408620T1/de active
- 2003-04-04 BR BR0309491-0A patent/BR0309491A/pt not_active IP Right Cessation
- 2003-04-04 ES ES03747137T patent/ES2312801T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1509543A2 (fr) | 2005-03-02 |
| AU2003249143B2 (en) | 2008-05-08 |
| ATE408620T1 (de) | 2008-10-15 |
| ES2312801T3 (es) | 2009-03-01 |
| FR2839072A1 (fr) | 2003-10-31 |
| US7314629B2 (en) | 2008-01-01 |
| DK1509543T3 (da) | 2008-12-15 |
| CA2483819A1 (fr) | 2003-11-06 |
| WO2003090667A3 (fr) | 2004-04-01 |
| WO2003090667A2 (fr) | 2003-11-06 |
| AU2003249143A1 (en) | 2003-11-10 |
| EP1509543B1 (fr) | 2008-09-17 |
| JP2005532298A (ja) | 2005-10-27 |
| US20060233820A1 (en) | 2006-10-19 |
| CA2483819C (fr) | 2013-01-22 |
| CN1656116A (zh) | 2005-08-17 |
| DE60323634D1 (de) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510622A5 (pt) | ||
| BR0309491A (pt) | Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes | |
| RS53505B1 (en) | OXYTOMODULIN PEPTIDE ANALOG | |
| NO20063026L (no) | Antistoffer | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| NO20031595L (no) | Vaksinesammensetning | |
| ATE267211T1 (de) | Impfstoff gegen hpv | |
| PE20040554A1 (es) | Vacunas que comprenden proteinas de fusion | |
| RU2005126236A (ru) | Фьюжн-белок для подавления цервикального рака | |
| JP2017522319A5 (pt) | ||
| JP2015504052A5 (pt) | ||
| RU2011154363A (ru) | Комбинации клад rrgb пневмококков | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| WO2007029262A3 (en) | Compositions and methods using same for the detection of viruses | |
| ATE246247T1 (de) | Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität | |
| PT914437E (pt) | Identificacao e clonagem de um antigenio micobacteriano correspondente a uma hemaglutinina de ligacao a heparina | |
| DK1913020T3 (da) | Immunogene konstrukter | |
| DK2076532T3 (da) | Cytokinderivater | |
| WO1999051188A3 (en) | A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof | |
| PE20010237A1 (es) | GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS OmpH, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS | |
| PE20010238A1 (es) | GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS SodC, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS | |
| PE20010316A1 (es) | GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS, PEPTIDOS Y PROTEINAS FlgE RELACIONADOS Y SUS USOS | |
| NZ570708A (en) | Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof | |
| WO2019059709A3 (ko) | Ｈｐ1404 펩타이드로부터 유래한 신규 항균 펩타이드 및 이의 용도 | |
| WO2006078268A3 (en) | A peptide that elicits neutralizing antibodies targeting the hiv co-receptor, ccr5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |